drugset / Trial / NCT02183493

Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects

NCT02183493

Phase 1 Completed 32 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the food effect on the relative bioavailability and pharmacokinetics of a 5 mg BI 1356 tablet administered as a single dose

Timeline

Start
2008-10
Primary completion
2008-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 5 mg

Indications

No indication recorded.